NASDAQ:OPGN

OpGen Stock Forecast, Price & News

$2.32
-0.21 (-8.30 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.32
Now: $2.32
$2.60
50-Day Range
$1.80
MA: $2.61
$3.07
52-Week Range
$1.63
Now: $2.32
$4.44
Volume1.57 million shs
Average Volume10.31 million shs
Market Capitalization$88.78 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.44
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firms products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
OpGen logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPGN
CUSIPN/A
Phone(301) 869-9683
Employees38
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.50 million
Book Value$0.77 per share

Profitability

Net Income$-12,450,000.00
Net Margins-586.99%

Miscellaneous

Market Cap$88.78 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Short Interest in OpGen, Inc. (NASDAQ:OPGN) Rises By 47.7%
April 1, 2021 |  americanbankingnews.com
Form 10-K OPGEN INC For: Dec 31 - StreetInsider.com
March 30, 2021 |  streetinsider.com
OpGen (NASDAQ:OPGN) Issues Earnings Results
March 26, 2021 |  americanbankingnews.com
OpGen, Inc. to Host Earnings Call - Yahoo Finance
March 25, 2021 |  finance.yahoo.com
OpGen's Earnings Outlook - Benzinga
March 25, 2021 |  benzinga.com
OpGen's Earnings Outlook
March 24, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

775th out of 2,021 stocks

Medical Laboratories Industry

11th out of 39 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$2.32
-0.21 (-8.30 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OpGen (NASDAQ:OPGN) Frequently Asked Questions

Is OpGen a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen
or view top-rated stocks.

What stocks does MarketBeat like better than OpGen?

Wall Street analysts have given OpGen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OpGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OpGen?

OpGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 873,400 shares, an increase of 47.7% from the February 28th total of 591,400 shares. Based on an average trading volume of 11,240,000 shares, the short-interest ratio is currently 0.1 days.
View OpGen's Short Interest
.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for OpGen
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings data on Wednesday, March, 24th. The medical research company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.06. The medical research company had revenue of $1.35 million for the quarter, compared to analysts' expectations of $1.30 million. OpGen had a negative net margin of 586.99% and a negative trailing twelve-month return on equity of 154.05%.
View OpGen's earnings history
.

How has OpGen's stock been impacted by Coronavirus?

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPGN shares have increased by 12.1% and is now trading at $2.32.
View which stocks have been most impacted by COVID-19
.

When did OpGen's stock split? How did OpGen's stock split work?

Shares of OpGen reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for OPGN?

2 equities research analysts have issued 1-year price objectives for OpGen's shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate OpGen's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 137.1% from the stock's current price.
View analysts' price targets for OpGen
or view top-rated stocks among Wall Street analysts.

Who are OpGen's key executives?

OpGen's management team includes the following people:
  • Oliver Schacht, Chief Executive Officer & Director
  • Johannes Bacher, Chief Operating Officer
  • Timothy C. Dec, CFO, Secretary & Chief Accounting Officer
  • Vadim Sapiro, Chief Information Officer
  • G. Terrance Walker, Senior Vice President-Research & Development

Who are some of OpGen's key competitors?

What other stocks do shareholders of OpGen own?

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $2.32.

How much money does OpGen make?

OpGen has a market capitalization of $88.78 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis.

How many employees does OpGen have?

OpGen employs 38 workers across the globe.

What is OpGen's official website?

The official website for OpGen is www.opgen.com.

Where are OpGen's headquarters?

OpGen is headquartered at 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at (301) 869-9683 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.